6533b82ffe1ef96bd1294650
RESEARCH PRODUCT
EGFR inhibition in NSCLC: New findings…. and opened questions?
Viviana BazanAlessandro PerezMarta CastigliaAntonio RussoFrancesco PassigliaSergio RizzoAngela Listìsubject
0301 basic medicineOncologyLung Neoplasmsmedicine.medical_treatmentAfatinibResistanceTreatment of lung cancerTargeted therapyTargeted therapyAntineoplastic Agent0302 clinical medicineEpidermal growth factorEpidermal growth factor receptorMolecular Targeted TherapybiologyHematologyTKIErbB ReceptorsOncology030220 oncology & carcinogenesisErlotinibReceptorHumanmedicine.drugmedicine.medical_specialtyEGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor Epidermal Growth Factor; Hematology; Oncology; Geriatrics and GerontologyEGFRProtein Kinase InhibitorAntineoplastic Agents03 medical and health sciencesGefitinibInternal medicinemedicineHumansLiquid biopsyIntensive care medicineProtein Kinase InhibitorsEGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor; Epidermal Growth Factor; Hematology; Oncology; Geriatrics and GerontologyEpidermal Growth FactorLiquid biopsybusiness.industryrespiratory tract diseasesLung Neoplasm030104 developmental biologyTKIsMutationbiology.proteinReceptor Epidermal Growth FactorGeriatrics and Gerontologybusinessdescription
The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent findings regarding EGFR-inhibition in NSCLC, highlighting the current unsolved questions on the selection of the best TKI in first-line, which therapy can be combined with upfront EGFR-TKIs, how to overcome acquired resistance, and which are the clinical applications of liquid biopsy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-04-01 |